Our discovery scientists “strive to make the impossible possible,” says Joe Miletich. And he should know: As the senior vice president of Discovery Preclinical and Early Development, he leads a team of researchers who are charged with making things “possible that weren’t possible before.” He continues: “At Merck, we believe drug discovery is foundational for us to continue bringing critical medicines to the world.”
About 14,500 people are involved in scientific research at Merck. Our U.S. R&D colleagues are located across the country — from Massachusetts to New Jersey to Pennsylvania to California — but they are all tasked with the same mission: to solve the puzzles of human disease biology and then translate those findings into new therapies for patients. They are driven to push the boundaries of science and to then transform their discoveries into meaningful new therapeutics.
“I think we always have a sense of urgency,” says Daria Hazuda, vice president of Infectious Diseases and Vaccines Discovery, and chief scientific officer of our recently launched Cambridge Exploratory Science Center. “We’re always driven to push the envelope, to push the frontier, to do something that nobody’s ever done before.”
“The ‘inspiration to invent’ remains our driving passion – and a proven path to dramatic advances in human health.”
— Ken Frazier, Merck chairman and CEO
Our teams never shy away from the hard work and many years it takes to invent a molecule with the potential to change the course of a disease - and a person's life. And that’s one reason why a commitment to unparalleled scientific research – to discovery and invention – remains at the heart of our business.
people are involved in Merck R&D. They share a commitment to turn breakthrough science into meaningful therapeutic options for patients.
Updated March 2019
Copyright. © 2009-2019 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved.
This website of Merck & Co., Inc., Kenilworth, NJ, USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation in the United States and internationally; global trends toward healthcare cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2015 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.
Merck is known as MSD outside the United States and Canada. Clicking on any of the links below will take you to a website intended for those living outside the United States and Canada.